A US bankruptcy judge on Monday rejected Johnson & Johnson’s $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer ...

Management anticipates higher growth in the second half of 2025, supported by newly launched products and pipeline ... efficiency improvements. Johnson & Johnson demonstrated resilience in Q1 ...

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and ...

Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies’ shareholders on March 27, 2025, ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on JNJ: Disclaimer & Disclosure Report an Issue Johnson & Johnson NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Johnson & Johnson’s Innovative Medicine contributes disproportionately higher profits. The concerns around the Stelara exclusivity appear overblown. China’s new tariffs just reignited the same ...

Robust data evaluating TECNIS Odyssey demonstrates outstanding patient outcomes with the new intraocular lens J&J to be included in 22 abst ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

Joaquin Duato; Chairman of the Board, Chief Executive Officer; Johnson & Johnson John Reed; Executive Vice President - Innovative Medicine, Research and Development; Johnson & Johnson Joseph Wolk; ...